EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An EGFR-Targeting Oxothiazolidinylidene Derivative: From Computational Design to Experimental Validation

Eslam B Elkaeed, Hazem Elkady, Walid E Elgammal, Ahmed Nofal, Hazem A Mahdy, Dalal Z Husein, Fatma G Amin, Aisha A Alsfouk, Ibrahim H Eissa, Ahmed M Metwaly

Journal of Chemical Research · 2026-03 · 50 (2)

DOI: 10.1177/17475198261442267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chemical Research, online erschienen am 26.04.2026. Verfasst von Eslam B Elkaeed und 9 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Princess Nourah Bint Abdulrahman University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An oxothiazolidinylidene derivative, Ethyl (Z)-2-((Z)-3-(4-acetamidophenyl)-2-(((E)-1-(4-acetamidophenyl)ethylidene)hydrazono)-4-oxothiazolidin-5-ylidene)acetate ( Z-EAHT ) was rationally designed and evaluated as a potential epidermal growth factor receptor inhibitor targeting both wild-type and T790M mutant forms. Computational analyses demonstrated favorable electronic properties, strong ATP-binding pocket compatibility, and stable protein–ligand interactions supported by 200 ns molecular dynamics simulations and Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) binding energy calculations. In silico ADME-Tox profiling predicted acceptable solubility, moderate absorption, and a favorable safety profile. Experimentally, Z-EAHT exhibited potent epidermal growth factor receptor inhibition (IC 50 = 0.012 µM for wild-type epidermal growth factor receptor; 0.013 µM for T790M mutant epidermal growth factor receptor) and demonstrated selective cytotoxicity against A549, MCF-7, and HepG-2 cancer cells while sparing normal WI-38 cells. Mechanistic investigations confirmed apoptosis induction and epidermal growth factor receptor downregulation. Overall, Z-EAHT emerged as a promising mutation-tolerant epidermal growth factor receptor inhibitor warranting further preclinical investigation.

Förderung

  • Princess Nourah Bint Abdulrahman University

Zitieren

APA

Elkaeed, E. B., Elkady, H., Elgammal, W. E., Nofal, A., Mahdy, H. A., Husein, D. Z., Amin, F. G., Alsfouk, A. A., Eissa, I. H., & Metwaly, A. M. (2026). An EGFR-Targeting Oxothiazolidinylidene Derivative: From Computational Design to Experimental Validation. Journal of Chemical Research, 50(2). https://doi.org/10.1177/17475198261442267

Vancouver

Elkaeed EB, Elkady H, Elgammal WE, Nofal A, Mahdy HA, Husein DZ, et al. An EGFR-Targeting Oxothiazolidinylidene Derivative: From Computational Design to Experimental Validation. Journal of Chemical Research. 2026;50(2). doi:10.1177/17475198261442267

BibTeX
@article{Elkaeed2026,
  author = {Elkaeed, Eslam B and Elkady, Hazem and Elgammal, Walid E and Nofal, Ahmed and Mahdy, Hazem A and Husein, Dalal Z and Amin, Fatma G and Alsfouk, Aisha A and Eissa, Ibrahim H and Metwaly, Ahmed M},
  title = {An EGFR-Targeting Oxothiazolidinylidene Derivative: From Computational Design to Experimental Validation},
  journal = {Journal of Chemical Research},
  year = {2026},
  volume = {50},
  number = {2},
  doi = {10.1177/17475198261442267}
}
Kostenlos starten →